COST-EFFECTIVENESS ANALYSIS OF TOFACITINIB IN THE TREATMENT OF ULCERATIVE COLITIS IN THE PERSPECTIVE OF BRAZILIAN PUBLIC HEALTHCARE SYSTEM

被引：0
|
作者：
Holanda, P. [1 ]
Salgado De Santana, C. [2 ]
Senna, T. [1 ]
Carmo, L. [1 ]
Alexandre, R. F. [1 ]
机构：
[1] Pfizer Inc, Sao Paulo, Brazil
[2] Pfizer Inc, Santos, SP, Brazil
来源：
VALUE IN HEALTH | 2021年 / 24卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PGI11
引用
收藏
页码：S96 / S96
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness of biological agents used in ulcerative colitis
    Lee, Jeannie K.
    Tang, Derek H.
    Mollon, Lea
    Armstrong, Edward P.
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2013, 27 (06) : 949 - 960
  • [42] Cost-effectiveness of colorectal cancer surveillance in ulcerative colitis
    Inadomi, JM
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2003, 38 : 17 - 21
  • [43] COST-EFFECTIVENESS OF ADALIMUMAB FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN CANADA
    Ghosh, S.
    Desjardins, O.
    Skup, M.
    Wang, S.
    Yang, M.
    Yang, H.
    Qi, C.
    Bao, Y.
    Chao, J.
    VALUE IN HEALTH, 2014, 17 (03) : A37 - A37
  • [44] COST-EFFECTIVENESS ANALYSIS OF TOFACITINIB FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS IN GREECE
    Gourzoulidis, G.
    Solakidi, A.
    Psarra, M.
    Nikitopoulou, E.
    Tzanetakos, C.
    VALUE IN HEALTH, 2023, 26 (12) : S57 - S57
  • [45] A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis
    Stawowczyk, Ewa
    Kawalec, Pawe
    PHARMACOECONOMICS, 2018, 36 (04) : 419 - 434
  • [46] Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis
    Wu, Bin
    Wang, Zhenhua
    Zhang, Qiang
    INFLAMMATORY BOWEL DISEASES, 2018, 24 (11) : 2291 - 2302
  • [47] Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland
    Petryszyn, Pawel
    Ekk-Cierniakowski, Pawel
    Zurakowski, Grzegorz
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2020, 13
  • [48] Cost-effectiveness of imatinib versus interferon-α in the treatment of patients newly diagnosed with chronic myeloid leukemia, under the Brazilian public healthcare system perspective.
    Mataveli, Fabio
    Calabro, Alessandra
    Mendes, Wellington
    Vianna, Denizar
    Dorlhiac-Llacer, Pedro
    Bigni, Ricardo
    Hungria, Vania
    BLOOD, 2006, 108 (11) : 946A - 946A
  • [49] COST-EFFECTIVENESS ANALYSIS OF THE ASPERGILLUS GALACTOMANNAN ENZYME IMMUNOASSAY IN THE BRAZILIAN PUBLIC HEALTH SYSTEM
    Barros, B.
    Magliano, C.
    Morais, Q. C.
    Leite, B. R.
    Leite, L. F. D. A.
    Mateus, I
    Braga, A.
    Santos, M.
    VALUE IN HEALTH, 2023, 26 (06) : S62 - S62
  • [50] Curcumin-QingDai combination for active ulcerative colitis: A cost-effectiveness analysis
    Yanai, H.
    Choi, D.
    Ben-Horin, S.
    Salomon, N.
    Loebstein, R.
    Leshno, M.
    Rubin, D. T.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1789 - i1789
12345